Underreported Potential Windfall for Largest Drug Store Chains

Bloomberg.com is running a story about an underreported potential windfall for the nation’s largest drug store chains Walgreen (WAG) and CVS Caremark (CVS). The reason for the optimism is the end of patent protection for the world’s two best selling drugs Lipitor and Plavix. Soon after blockbuster drugs lose patent protection is a very profitable time for drug stores as they have more control over pricing, and even though generic drugs are cheaper than branded drugs, they generally provide better profit margins for the pharmacies. According to the article, pharmacies pay 90% less for the generics, but do not pass all of those savings on to end consumers.

Bigger and Longer

The last large wave of patent expirations came in 2006 and 2007, when branded drugs generating sales of $43 billion faced generic competition, according to Norwalk, Connecticut-based IMS Health Inc., a market research firm. That helped boost CVS earnings per share by 20 percent in 2007 and Walgreen’s by 19 percent in the fiscal year that ended in August 2007.

“This cycle is bigger and it’s longer” than the introduction of generic drugs in 2006 and 2007, Taner, the Invesco fund manager, said in an interview. Invesco increased its holdings to 5.68 million Walgreen shares and 5.96 million CVS shares as of Sept. 30, according to Bloomberg data.

CVS and Walgreen will also benefit because they have expanded in recent years, gaining pricing power, said Massey, the SunAmerica investor. Still, prices pharmacies pay for drugs won’t drop as much in the next cycle because there are fewer manufacturers as a result of mergers. — Bloomberg.com 2/5/2010

Current analysts’ estimates call for CVS to grow earnings by 11% in 2011 and 14% in 2012, and Walgreen is expected to grow at 17% in both years. However, judging by the explosive earnings growth of the last major wave of generics, even those impressive estimates may be too tame. All other things being equal, earnings growth of this magnitude would surely drive both stocks higher.

Generic alternatives for Lipitor and Plavix will not be available and therefore accretive to earnings until early 2012 at the earliest. Even at current estimates for forward-looking earnings, we think both of these stocks are Undervalued at the current price level. We selected WAG as one of our Five Blue Chips Fit For Ben Graham when asked to do a special report for Forbes.com early last September, and the stock’s price is at about the same as it was then. At that time, we were not aware that the new wave of generic drugs was as promising as it appears to be, and we continue to believe that both of these stocks have substantial value to investors. Both stocks have sold off heavily in the past three trading sessions which generally makes these stocks even more attractive to long term, value investors.

About Ockham Research 645 Articles

Ockham Research is an independent equity research provider based in Atlanta, Georgia. Security analysis at Ockham Research is based upon the principle known as Ockham's Razor, named for the 14th- century Franciscan friar, William of Ockham. The principle states that a useful theory should utilize as few elements as possible, because efficiency is valuable. In this spirit, our goal is to make the investing environment as simple and understandable as possible, yet no simpler than is necessary.

We utilize this straightforward approach to value over 5500 securities, with key emphasis given to the study of individual securities' price-to-sales, price-to-cash earnings and other historical valuation ranges. Our long term value investing methodology is powered by the teachings of Ben Graham and it has proven to be very adept at identifying stock prices that are out of line with fundamental factors.

Ockham Research provides its research in a variety of forms and products including our company specific reports, portfolio analytics tools, newsletters, and blog posts. We also offer a white labeling research solution that can give any financial services firm their own research presence without the time and cost associated with building such a robust coverage universe of their own.

Be the first to comment

Leave a Reply

Your email address will not be published.